| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,370,000 |
| Market
Cap: |
776.74(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0401 - $1.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2017-02-09 |
4 |
B |
$14.27 |
$587,928 |
I/I |
41,211 |
4,134,547 |
1.5 |
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2017-02-08 |
4 |
B |
$13.51 |
$1,413,319 |
I/I |
104,612 |
4,093,336 |
1.5 |
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-02-03 |
4 |
AS |
$13.69 |
$91,983 |
D/D |
(6,719) |
213,858 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-02-02 |
4 |
AS |
$13.51 |
$94,205 |
D/D |
(6,973) |
220,577 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-02-02 |
4 |
OE |
$2.53 |
$10,540 |
D/D |
4,166 |
227,550 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-02-01 |
4 |
AS |
$13.95 |
$91,735 |
D/D |
(6,576) |
223,384 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-02-01 |
4 |
OE |
$2.53 |
$16,637 |
D/D |
6,576 |
229,960 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-01-31 |
4 |
AS |
$13.40 |
$147,385 |
D/D |
(10,662) |
223,384 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-01-31 |
4 |
OE |
$2.53 |
$26,975 |
D/D |
10,662 |
234,046 |
|
- |
|
| Brumm Joshua T |
COO and CFO |
• – – |
2017-01-30 |
4 |
S |
$13.85 |
$40,794 |
D/D |
(2,945) |
105,779 |
|
- |
|
| Westberg Paul |
SVP and Chief Business Officer |
• – – |
2017-01-30 |
4 |
S |
$13.85 |
$26,540 |
D/D |
(1,916) |
69,544 |
|
- |
|
| Ward Shane |
SVP and General Counsel |
• – – |
2017-01-30 |
4 |
S |
$13.85 |
$20,418 |
D/D |
(1,474) |
38,391 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-01-30 |
4 |
AS |
$13.31 |
$233,468 |
D/D |
(17,270) |
223,384 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-01-30 |
4 |
OE |
$2.53 |
$26,808 |
D/D |
10,596 |
233,980 |
|
- |
|
| Brumm Joshua T |
COO and CFO |
• – – |
2017-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
43,900 |
108,724 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2017-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
19,500 |
24,500 |
|
- |
|
| Westberg Paul |
SVP and Chief Business Officer |
• – – |
2017-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
26,860 |
71,460 |
|
- |
|
| Ward Shane |
SVP and General Counsel |
• – – |
2017-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,600 |
39,865 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
74,700 |
230,058 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2017-01-11 |
4 |
AS |
$15.24 |
$120,868 |
D/D |
(7,931) |
44,600 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2017-01-11 |
4 |
OE |
$1.61 |
$12,769 |
D/D |
7,931 |
52,531 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2017-01-10 |
4 |
AS |
$15.66 |
$175,596 |
D/D |
(11,213) |
44,600 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2017-01-10 |
4 |
OE |
$1.38 |
$15,646 |
D/D |
11,213 |
55,813 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2017-01-09 |
4 |
AS |
$15.93 |
$212,761 |
D/D |
(13,356) |
44,600 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2017-01-09 |
4 |
OE |
$1.27 |
$18,165 |
D/D |
13,356 |
57,956 |
|
- |
|
258 Records found
|
|
Page 6 of 11 |
|
|
